Coronavirus (COVID-19) - Latest Information for Patients and Visitors

(La más reciente información para pacientes y visitantes)

 

Read Now (Lea ahora)
800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

COVID-19 Clinical Trials

Researchers and clinicians at Temple Health and the Lewis Katz School of Medicine are conducting many clinical trials for the prevention, early identification and treatment of COVID-19. Learn more below about our active clinical trials that address the COVID-19 pandemic.

Interested in participating in any of these clinical trials? View more information about the trials to find out if you qualify and how to enroll.

Outpatient Clinical Trials

Safety, Tolerability, And Efficacy Of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies For The Treatment Of Ambulatory Adult Patients With COVID-19

Investigator: Gerard Criner, MD

This study will evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo and to evaluate the virologic efficacy of REGN10933+REGN10987 compared to placebo in reducing viral shedding of SARS-CoV-2.

A Study Of LY3819253 (LY-CoV555) In Participants With Mild To Moderate COVID-19 Illness (BLAZE-1)

Investigator: Gerard Criner, MD

The purpose of this study is to measure how well LY3819253 works against the virus that causes COVID-19. LY3819253 will be given to participants with early symptoms of COVID-19, via an injection into a vein.

Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Investigator: Gerard Criner, MD

The primary objective is to evaluate the efficacy of REGN10933+REGN10987 compared to placebo in preventing asymptomatic or symptomatic SARS-CoV-2 infection confirmed by RT-qPCR, as well as to evaluate the safety and tolerability of REGN10933+REGN10987 following subcutaneous (SC) administration compared to placebo.

Inpatient Clinical Trials

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Patients With Acute COVID-19 Disease

Investigator: Gerard Criner, MD

This is a Phase 2 trial to evaluate the efficacy and safety of intravenous (IV) infusions of pamrevlumab as compared to placebo in hospitalized subjects with acute COVID-19 disease.

A Study Of Baricitinib (LY3009104) In Participants With COVID-19 (COV-BARRIER)

Investigator: Roberto Caricchio, MD

The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.

Safety, Tolerability, And Efficacy Of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies For Hospitalized Adult Patients With COVID-19

Investigator: Gerard Criner, MD

The purpose of this study is to evaluate the safety and tolerability, virologic efficacy, and clinical efficacy of REGN10933+REGN10987 compared to placebo in various instances.

Expanded Access To INOpulse® Inhaled Nitric Oxide Therapy For Patients With Confirmed Or Suspected COVID-19 Who Require Supplemental Oxygen

Investigator: Jeffrey Stewart, MD

The primary objective of this study is to evaluate disease progression in spontaneously breathing COVID-19 patients receiving INOpulse® treatment. This is NOT a clinical trial. Rather, it is an investigational treatment made available through the FDA's Emergency Expanded Access program.

Convalescent Plasma in Outpatients With COVID-19 (C3PO)

Investigator: Nina Gentile, MD

The primary objective is to determine the efficacy and safety of a single dose of convalescent plasma (CP) for preventing the progression from mild to severe COVID-19 illness. The secondary objective is to characterize the immunologic response to CP administration.

RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM (STORM)

Investigator: Arthur M. Feldman, MD, PhD

The primary aim of this study is to test whether Doxycycline can benefit patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections by inhibiting the replication of the virus while at the same time blocking the development of cytokine storms or inhibiting cytokine-associated coagulopathy respectively.

Healthcare Worker Exposure Response and Outcomes (HERO) Registry

The HERO Registry is a national clinical research community. It asks healthcare workers across the country to share their experiences, and aims to better understand the impact that the COVID-19 pandemic has on you, your colleagues, family and friends.

The HERO Registry is open to anyone who works in a healthcare setting, including nurses, therapists, physicians, emergency responders, food service workers, environmental service workers, interpreters and transporters.

Learn more and join the registry >